Article

3 Iconography
1 Complement
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Joint Bone Spine
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le samedi 12 octobre 2019
Doi : 10.1016/j.jbspin.2019.08.001
accepted : 29 August 2019
Exposure to TNF antagonist therapies induces variations of the gut microbiota in an in vivo model using healthy mice
 

Odile Gabay a, , Jonathan Vicenty a, Autumn Zack-Taylor a, Linda Tiffany a, Grant Wunderlin a, Dylan Smith a, Lismari Reyes-Munoz a, Vivienne Edwards a, Wells W. Wu b, Je-Nie Phue b, Luis Santana-Quintero d, Phuc VinhNguyen Lam c, Kathleen A. Clouse a
a U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Biotechnology Review and Research 1, Silver Spring, MD, USA 
b U.S. Food and Drug Administration, Center for Biologicals Evaluation and Research, Facility for Biotechnology Resources, Silver Spring, MD, USA 
c U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Biostatistics and Epidemiology, HIVE, Silver Spring, MD, USA 
d U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drugs, Office of Hematology and Oncology Products, Silver Spring, MD, USA 

Corresponding author at: FDA/CDER White Oak, Division of Biotechnology Review and Research, Bldg 52/72, Rm2321, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.FDA/CDER White Oak, Division of Biotechnology Review and Research, Bldg 52/72, Rm232110903 New Hampshire AvenueSilver SpringMD20993USA
Highlights

There is currently no study on the impact of biologic therapeutics on the microbiome, despite variable patients’ response to biologics used to treat gut-joint-axis diseases.
We studied microbiome variations resulting from different TNF-antagonist treatments in an in vivo mouse model.
We showed a dysbiosis of the microbiome after treatment in young mice, and identified major bacteria involved in TNF-antagonists exposure. These bacteria were different between males and females.

The full text of this article is available in PDF format.

Keywords : Gut microbiome, TNF inhibitors, Dysbiosis



 Disclaimer: This manuscript reflects the views of the authors and should not be construed to represent FDA's views or policies.



© 2019  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline